Updated: Mar 22, 2021 14:56 IST
Mumbai (Maharashtra) [India], March 22 (ANI/PRNewswire):
Under the terms of the agreement, will be responsible for regulatory approvals and supply of RYALTRIS for the Canadian market. , Canada will be responsible for the commercialization of RYALTRIS in the Canadian market, following regulatory approval. will receive an upfront payment, launch & sales-based milestone payments in addition to royalties and supply price from sales of RYALTRIS.
RYALTRIS (Olopatadine Hydrochloride 665 mcg and Mometasone Furoate 25 mcg), is currently under review by Health Canada with a proposed indication for the treatment of seasonal allergic rhinitis in adults and children over 12 years of age.
Commenting on the agreement, Sanjeev Krishan, President & Business Head – North America,
“We are pleased to add Ryaltris to our allergy product portfolio and eager to make it available to Canadian patients suffering from allergies,” said Richard Lajoie, President of , Canada.
In Canada, allergic rhinitis is estimated to afflict 25 per cent of the population and can have a significant impact on sleep, work and school performances. When approved in Canada, RYALTRIS will offer a fixed-dose combination of two different classes of medications in a convenient nasal spray presentation. A combination of intranasal antihistamines and intranasal corticosteroids may be beneficial and provide an additive effect on efficacy, resulting in superior relief of seasonal allergic rhinitis symptoms compared with monotherapyii.
This story is provided by PRNewswire. ANI will not be responsible in any way for the content of this article. (ANI/PRNewswire)